Select Your Region

We noticed you visit this page from United States. Please select your preferred region to continue.

skip to content

Country Selector

Based on your location

Europe

North America

Latin America

Asia-Pacific

Company Overview

Our new language of life: a commitment to improve people health worldwide.

Our mission 

Our mission is to provide healthcare professionals with powerful tools that translate complex biological signals into clear, actionable insights.

We call it our new language of life.

This language helps reveal the biological signatures behind complex and chronic diseases, enabling earlier detection, more accurate diagnosis and better patient management. From oncology and hematology to autoimmune, metabolic and infectious diseases, many conditions are driven by subtle changes in proteins, antibodies and other biomarkers that require specialized analytical approaches to be fully understood.

At Sebia, we combine scientific expertise, innovative technologies and deep clinical knowledge to make these biological patterns visible and clinically meaningful.

Who We Are

Sebia is a global specialized In Vitro Diagnostic company providing systems and reagents for the screening, diagnosis and monitoring of diseases in Oncology, Diabetes, Hemoglobinopathies, Autoimmune and Infectious Diseases, as well as other rare disorders.

Founded in 1967 and headquartered near Paris, France, Sebia has built a unique expertise in specialty diagnostics and protein analysis. In the early 2000s, the company pioneered the introduction of Capillary Electrophoresis in clinical diagnostics, establishing a new standard for automation, performance and diagnostic confidence.

Today, while continuing to advance its leadership in Capillary Electrophoresis, Sebia is expanding its footprint in autoimmunity, bringing innovative solutions that complement its historical strengths and support clinicians across a broader spectrum of patient needs.

Driven by scientific excellence, technological innovation and strong manufacturing capabilities, Sebia continues to develop new assays and automated platforms that help laboratories deliver answers that matter for patients worldwide.

  • 1,500+

    employees worldwide

  • 23

    affiliates and representative offices

  • 6

    manufacturing sites

  • 120+

    countries served

  • 20k+

    instruments installed worldwide

Our mission is to provide powerful tools that translate what is happening in a patient's body into a readable and interpretable language.

Our history

Your Specialty Diagnostic Company, built on 60+ years of trusted expertise, empowering laboratories and healthcare professionals worldwide with innovative solutions to detect, monitor, and understand diseases—from oncology, diabetes and hemoglobinopathies to autoimmune and rare disorders.

  • 1967

    Guy Barouh establishes Sebia

  • 1986

    Launch of the HYDRAGEL range of products

  • 1986

    Opening of the German subsidiary

  • 1994

    Introduction of the First HYDRASYS system

  • 1996

    Opening of the BeNeLux subsidiary

  • 1997

    Opening of the U.S. subsidiary

  • 1998

    Opening of the Italian subsidiary

  • 2001

    Sebia introduces Capillary Electrophoresis (CE) technology

  • 2001

    Opening of the Spanish subsidiary

  • 2004

    Opening of the Lisses Headquarters in France

  • 2005

    First CAPILLARYS 2 system sold

  • 2006

    Opening of the UK subsidiary

  • 2007

    Introduction of CE test for Hb

  • 2007

    Opening of subsidiaries in China and Brazil

  • 2011

    Introduction of a CE test for HbA1c

  • 2015

    First CAPILLARYS 3 TERA system sold

  • 2016

    Acquisition of Interlab

  • 2017

    Introduction of the CAPILLARYS 3 TERA MC system

  • 2017

    Jean-Marc CHERMETTE is named CEO

  • 2018

    Opening of the Swiss subsidiary

  • 2019

    Extended CAPILLARYS 3 Family of Instruments (OCTA & TLA System)

  • 2019

    Opening of subsidiaries in Portugal, India and UAE

  • 2020

    Opening of the Canadian subsidiary

  • 2021

    First CAPILLARYS 3 DBS system sold

  • 2021

    Opening of subsidiaries in Singapore and Japan

  • 2021

    Acquisition of Orgentec & launch of Alegria 2

  • 2022

    Opening of subsidiaries in South Korea, the Czech Republic, Slovakia and Hungary

  • 2022

    Acquisition of Zeus Scientific

  • 2023

    Opening of subsidiaries in Sweden & Romania

  • 2024

    Launch of the IFA Automation Family of Instruments

  • 2026

    Opening of the Australian subsidiary

  • 2026

    Launch of the Alegria Flash

Learn more

  • Within the Sebia Group everything is possible. If you want to live a great professional adventure, Join us!

  • Over the years, Sebia has continuously strengthened its international footprint to better serve its customers.

Employee testimonials